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Navneet S. Majhail, Jaya M. Mothukuri, Claudio G. Brunstein, Daniel J. WeisdorfAllogeneic hematopoietic cell transplantation (HCT) is a complex and costly procedure. Unrelated umbilical
cord blood (UCB) is an alternative graft source for patients without matched related donors (MRD); how-
ever, costs of UCB HCT have not been described. We compared the costs of HCTwithin the first 100 days
among recipients of MRD (myeloablative 5 67, nonmyeloablative5 54) or UCB (myeloablative 5 63, non-
myeloablative 5 110) HCT. Cost and hospitalization data were obtained from the institutional accounting
department. The 100-day probabilities of overall survival (OS) and cumulative incidence of treatment-related
mortality (TRM) were comparable among 4 transplant types; however, neutrophil recovery was delayed and
graft failure was more likely in UCB recipients. The median cost per day survived (excluding costs of graft
acquisition) was $1016 for myeloablative MRD, $2082 for myeloablative UCB, $612 for nonmyeloablative
MRD, and $1156 for nonmyeloablative UCB recipients, respectively (P\.001). In multivariate analysis, ad-
justing for important patient, disease, and HCT-related characteristics, as well as major post-HCT complica-
tions, factors associated with higher costs within the first 100 days were myeloablative UCB HCT (relative
risk 1.3 [95% confidence intervals, 1.1-1.5] versus myeloablativeMRDHCT), graft failure (1.8 [1.7-1.9]), need
for dialysis (1.3 [1.1-1.5]) or mechanical ventilation (1.3 [1.2-1.4]) and total hospital stay in the highest tertile
(.48 days; 2.1 [1.9-2.3]). The median cost per day survived for patients with graft failure was $6976 (versus
$1105 for no graft failure), dialysis was $4764 (versus $1102 for no dialysis), and $5099 for mechanical ven-
tilation (versus $977 for no mechanical ventilation). Within the first 100 days, the absolute costs of myeloa-
blative and nonmyeloablative UCB are higher than myeloablative and nonmyeloablative MRD transplantation.
These costs are primarily driven by severe posttransplant complications, graft failure, and prolonged inpa-
tient stay. Strategies to enhance engraftment will decrease the costs of UCB transplantation.
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CostsINTRODUCTION
Although hematopoietic cell transplantation
(HCT) has the potential to cure high-risk hemato-
logic and nonhematologic disorders, it is a complex,
resource-intense, and costly procedure. Costs of
transplantation can include charges for delivery ofBlood and Marrow Transplant Program, University of
esota, Minneapolis, Minnesota.
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6/j.bbmt.2009.01.011care (eg, physician charges), supportive care (eg,
blood product transfusions), graft procurement,
hospitalization, pharmacy, and laboratory and
radiologic investigations. Also, despite major
advances in transplant techniques and supportive
care practices, HCT continues to be associated
with substantial treatment-related mortality (TRM)
such as infections, organ failure, and graft-versus-
host disease (GVHD), and management of these
complications can further increase the overall cost
of posttransplant care. Studies of transplantation
costs are complex and difficult to conduct because
of the wide variation in transplant methods, condi-
tioning, and GVHD prophylaxis regimens and sup-
portive care practices. However, studies have
described costs of allogeneic HCT using either
myeloablative or nonmyeloablative conditioning
regimens, and show that HCT in general is an
Biol Blood Marrow Transplant 15:564-573, 2009 565Costs of Hematopoietic Cell Transplantationexpensive procedure, and occurrence of complica-
tions after transplantation increases overall medical
costs [1-10].
Introduction of unrelated umbilical cord blood
(UCB) as an alternative graft source for patients with-
out amatched related donor (MRD) is among themost
significant recent breakthroughs in the field of trans-
plantation. UCB has the advantages of rapid availabil-
ity, and may be associated with lower risks of GVHD,
despite the use of units with higher HLA disparity
[11,12]. Our group has described the use of UCB
HCT in adults, especially using 2 UCB units to opti-
mize cell dose with outcomes comparable to that
seen with other donor sources [13-15]. However, use
of UCB is associated with delayed engraftment and
a higher risk of graft failure. Incremental experience
is rapidly leading to adoption of UCB as an alternative
donor source by many transplant centers. A better un-
derstanding of the costs of UCBHCT is of importance
from the health care resource utilization and health
policy perspective, and can also assist in comparison
of cost-effectiveness of UCB with other alternative
(eg, matched unrelated donor and haploidentical) do-
nor sources. Identification of specific factors that
may be predictive for UCB transplant costs can help
with the development of strategies to reduce costs
while maintaining outcomes with a resultant increase
in the applicability of UCB HCT.
We conducted a retrospective cohort study in
a contemporary group of adult HCT recipients to
evaluate the costs of myeloablative and nonmyeloabla-
tive UCBHCT, and to compare themwith the costs of
myeloablative and nonmyeloablative MRDHCT.We
also explored various risk factors for their association
with increased costs of HCT.PATIENTS AND METHODS
Patients
The study cohort consisted of consecutive patients
who received an allogeneic HCT between 2004 and
2006, and were $18 years of age at the time of trans-
plantation. From the 318 eligible patients, 24 were ex-
cluded: recipients of planned autologous HCT
followed by nonmyeloablative allogeneic sibling donor
HCT for multiple myeloma (MM;N5 12), and recip-
ients of matched unrelated donor grafts (N 5 12).
Hence, the final study cohort consisted of 294 patients.
Transplant-related and outcome data were retrieved
from the University of Minnesota Blood and Marrow
Transplant Program Database, which prospectively
collects these data on all patients transplanted at our
institution. Additional data for this study were ab-
stracted from patient medical records. Patients were
treated on clinical protocols approved by our institu-
tional review board.Conditioning regimen intensity (myeloablative
[MA] versus nonmyeloablative [NMA]) was prospec-
tively determined by transplant protocols. Specific in-
dications for HCT using NMA conditioning were
older age ($55 years for MRD and $45 years for
UCB), presence of significant comorbidity (serious or-
gan dysfunction, invasive mold infection within 3
months before transplantation or Karnofsky perfor-
mance score of 50-60), or previous extensive prior
therapy (.12 months of alkylator-based chemother-
apy, .6 months of alkylator-based chemotherapy
and extensive radiation, or history of autologous trans-
plantation). Patients received UCB as a graft source if
they had no HLA-compatible related donors. Our
UCB selection criteria for adults have been previously
published and allow the use of 2UCB units to optimize
cell dose, if necessary [12].
Patients were classified as having standard or high
risk disease. Standard risk disease included acute leu-
kemia in first complete remission (CR1), chronic my-
elogenous leukemia (CML) in first chronic phase,
myelodysplastic syndrome (MDS) (refractory anemia
only), and nonmalignant hematologic disorders; all
other diagnoses were categorized as high-risk disease.Conditioning Regimen and Supportive Care
MA and NMA regimens used at our institution
have been described previously [13,14,16]. Briefly, pa-
tients undergoing MAMRDHCT received a regimen
consisting of total-body irradiation (TBI) and cyclo-
phosphamide (Cy), whereas recipients of MA UCB
HCT received TBI, Cy, and fludarabine (Flu).
NMA regimens for both MRD and UCB recipients
consisted of TBI, Cy, and Flu. The TBI dose in MA
regimens was 1320 cGy (165 cGy twice daily 4
days) and in NMA regimens was 200 cGy (single frac-
tion). Our GVHD prophylaxis and treatment regi-
mens have also been described previously [17]. All
patients received GVHD prophylaxis with cyclospor-
ine (CsA; days23 to at least1100), with trough levels
maintained between 200 and 400 ng/mL and either
methotrexate (MTX; in MA MRD recipients) or
mycophenolate mofetil (MMF; in MA and NMA
UCB and NMA MRD recipients; days 23 to at least
130).
Outpatient clinical evaluation to determine eligi-
bility for transplantation was performed within 30
days prior to transplantation for all patients, and in-
cluded history and physical examination, bone marrow
biopsy and aspirate evaluation, assessment of organ
function, determination of infectious markers, and ap-
propriate radiologic imaging or other investigations
for disease staging. Allogeneic HCT recipients were
then admitted to the inpatient unit for initiating condi-
tioning therapy and were discharged from the hospital
after they had engrafted (absolute neutrophil count
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take, had transfusion or other infusion requirements
that could be met as an outpatient, and had no compli-
cations requiring continued hospitalization. Fre-
quency of outpatient follow-up was based on patient
overall clinical condition and need for ongoing sup-
port (eg, transfusions, antibiotic infusions). All apher-
esis procedures for MRD peripheral blood stem cell
(PBSC) collection were performed as an outpatient.
All patients received antibacterial, antiviral, and anti-
fungal prophylaxis and blood product and nutritional
support per institutional guidelines. Granulocyte-col-
ony stimulating factor (G-CSF) was administered to
all patients until the ANCwas.2.5 109/L for 2 days.
All patients are followed within our transplant pro-
gram and institution from the time of pretransplant
evaluation until at least 100 days posttransplant. Pa-
tients are required to stay within a 30-min driving dis-
tance from our transplant center, and accommodation
is arranged for patients who do not live locally. All hos-
pitalizations within the first 100 days are exclusively in
a dedicated inpatient transplant unit that has resources
for management of severe post-HCT complications
(eg, mechanical ventilation, dialysis, pressor support).
All outpatient visits within the first 100 days occur in
our transplant clinic, which has infusion chairs and re-
sources for performing minor procedures. Hence, our
institutional accounting department captures all rele-
vant medical costs for the first 100 days except costs
for outpatient prescription drugs, including drugs
administered through home-care services. Trans-
plant-related care in this early posttransplant period
was coordinated by our group of transplant physicians
and midlevel providers who periodically rotate
through both the inpatient and outpatient services
and take care of all HCT recipients irrespective of their
underlying diagnosis or transplant type. Therefore, in-
dividual providerpractice variationdidnothave amajor
influence on costs within specific transplant types in
our analysis.Cost Data
Data regarding inpatient costs, days of hospitaliza-
tion, and number of outpatient clinic visits were ob-
tained from the institutional accounting department
for all transplant-related costs prior to day 0 (from
day230) and until day 100 posttransplantation. Costs
were determined by each hospital department’s item
and procedure specific costs and then summed from
the itemized listing of each patient’s hospital account-
ing record through day 100. Besides total cost of care
(direct and indirect costs), specific categories of costs
were also available. These categories included costs
for ‘‘graft acquisition,’’ ‘‘laboratory services,’’ ‘‘radio-
logic investigations,’’ ‘‘pharmacy services,’’ ‘‘room and
board,’’ ‘‘blood components,’’ and ‘‘other services.’’Examples of ‘‘other service’’ costs include costs for
occupational therapy, physical therapy, and vascular
access and operating room costs. We excluded costs
for ‘‘physician services.’’ Also, we could not account
for outpatient prescription drug costs and did not in-
clude patient related nonmedical costs (eg, out-of-
pocket costs, transportation, and accommodation) in
our analysis.
Costs for ‘‘graft acquisition’’ consisted of costs for
donor evaluation, apheresis procedure, and graft pro-
cessing and storage for MRD HCT. For UCB recipi-
ents, this category included costs for searching the
cord blood bank inventory, confirmatory HLA-typing
of the cord blood unit, and shipping of the product.
Median graft acquisition costs were $9566 for MRD
and $68,830 for UCB transplantation. Although pa-
tients receiving matched unrelated donor HCT were
excluded from this study, their median graft acquisi-
tion costs were $55,121. We excluded costs for graft
acquisition from further cost analyses, as we wanted
to specifically focus on the impact of posttransplant
events on total costs. However, graft acquisition costs
for a second graft infusion for graft failure or donor
lymphocyte infusion for relapse within the first 100
days were included in cost analyses and were combined
with the ‘‘other’’ category.
Because our data consisted of the actual dollar
amount for cost incurred and given the relatively con-
temporary nature of our cohort, we did not adjust for
inflation in our cost analyses.Statistical Methods
The primary endpoint of this study was to compare
medical costs among recipients of MA and NMA
MRD and UCB transplantation. We also wanted to
explore factors that were associated with increased
costs of transplantation. To simplify comparison
among different transplant categories, especially be-
cause of the variation in patient selection, risks for
transplant-related complications and overall out-
comes, costs are presented as cost per-day survived
(in dollars).
Data are described as proportions or as median
with range or interquartile range (lowest quartile-
highest quartile). Comparison of patient, disease, and
transplant characteristics was performed using chi-
square, Fisher’s exact, or Wilcoxon’s rank sum test as
appropriate. Cumulative incidence of engraftment,
TRM, and GVHD was calculated by treating deaths
from other causes as competing risks. The Kaplan-
Meier method was used to plot curves for overall
survival (OS). Multivariate Cox regression analysis
was performed for OS after including the following
variables: transplant type (main effect variable), age
at HCT, sex, Karnofsky performance status at HCT,
disease risk, previous HCT, cytomegalovirus (CMV)
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iii-iv), graft failure, dialysis, mechanical ventilation,
and hepatic veno-occlusive disease (VOD). Event
times were measured from date of transplantation to
date of death or last contact.
Analysis of variance (ANOVA) method was used to
compare costs among different transplant types and
was adjusted for the following variables: age at HCT,
Karnofsky performance status at HCT, disease risk,
previous HCT, CMV status, aGVHD (grade iii-iv),
graft failure, dialysis, mechanical ventilation, hepatic
VOD, duration of hospital stay (days of initial and
any subsequent hospitalizations), and number of total
medical encounters (days of hospitalization and outpa-
tient clinic visits). HLA-match status correlated with
transplant type and was not included as a separate vari-
able. There were no significant interactions between
transplant type and other predictor variables included
in the ANOVA models.
All P-values reported are 2 sided. Analyses were
performed using the SAS 9.1 software (Cary, NC).RESULTS
Patient and Transplant Characteristics
Patient, disease, and transplant characteristics of
our cohort are described in Table 1. As expected, re-
cipients of NMA conditioning were older than those
who received MA conditioning. The majority of pa-
tients who underwent UCB HCT (95%) received 2
cord blood units to optimize cell dose.MRD recipients
were more likely to receive a 6/6 HLA matched graft
(93% versus 9% for UCB). UCB recipients had slower
neutrophil and platelet engraftment, had higher inci-
dence of graft failure, and weremore likely to have lon-
ger hospital stay compared to MRD recipients. The
rates of major complications (dialysis, mechanical ven-
tilation, or hepatic VOD) were similar among all types
of allogeneic HCT.
Patient Survival and Outcomes
Probability of OS and cumulative incidences of
TRM and aGVHD (grade iii-iv) in the first 100 days
posttransplant were comparable among the 4 types of
allogeneic HCT (Table 2). Transplant type was not
predictive for OS on multivariate analysis (Table 3).
Factors independently associated with increased risk
of overall mortality included graft failure (relative
risk [RR] 3.6, 95% confidence intervals [CI] 2.2-5.9),
need for dialysis (RR 2.1, 95% CI 1.4-3.3), and need
for mechanical ventilation (RR 4.4, 95% CI 3.1-6.2).
Costs of Transplantation
Themedian total cost of transplantation (excluding
graft acquisition costs) within the first 100 days was$137,112 (interquartile range [IQR], 97,658-225,430)
for MA and $84,824 (IQR, 52,247-151,906) for NMA
allogeneic HCT, respectively (P\ .001). The median
total cost for UCB HCT was $137,564 (IQR,
$81,486-$256,451) compared with $83,583 (IQR,
$60,783-$123,581) for MRD HCT ( p\ .001). UCB
HCTusing eitherMA orNMA conditioning was asso-
ciated with significantly higher costs than MRDHCT
(Table 4). Themedian cost per day survivedwas $1,016
forMA and $612 for NMAMRDHCT and was $2082
forMAand$1156 forNMAUCBHCT(P\.001). For
purposes of comparison, the median cost per day sur-
vived for matched unrelated donor HCT was $1586
for MA and $650 for NMA conditioning; however,
these patients were excluded from further analyses be-
cause of small patient numbers.
The categories of cost for different transplant
types are summarized in Figure 1. In general, the ma-
jor contributors of cost for all transplant types were
room and board and pharmacy services. MA and
NMA UCB HCT recipients had longer hospitaliza-
tions, and as a result, had higher costs for room and
board compared to recipients of MRD HCT. Phar-
macy and laboratory services are more likely to be uti-
lized during inpatient stay, and, hence, costs for these
services were higher following UCB HCT. Because
UCB transplant recipients also had a longer time to
platelet engraftment, it was associated with higher
blood component costs.
The contribution of various cost categories to total
costs did not differ significantly among patients with
low, intermediate, or high costs of care (Figure 2).
However, the contribution of costs for blood compo-
nents was relatively higher among patients whose
care was themost expensive (total cost per day survived
in the highest tertile, .$1805) compared with those
with the least total costs (total cost per day survived
in the lowest tertile,\$830).Predictors of Cost
In multivariate analysis that adjusted for various
factors that could influence costs (Table 5), MA
UCB HCT was associated with higher costs than
MA MRD HCT, but this difference was marginally
significant (RR 1.3, 95%CI 1.1-1.5, P5 .05). Interest-
ingly, the costs of NMA MRD and NMA UCB HCT
were similar to those ofMAMRDHCT.More impor-
tant predictors of costs were graft failure, need for
dialysis, need for mechanical ventilation, and very
long hospital stay. This is summarized in Table 6 and
Figure 3, which highlights that patients with total costs
in the highest tertile had a higher proportion of these
risk factors compared to those with costs in the middle
or lowest tertiles.
The median total cost per day survived for 23 pa-
tients with graft failure (MRD 5 2, UCB 5 21) was
Table 1. Patient, Disease, and Transplant Characteristics
Variable MA MRD MA UCB NMA MRD NMA UCB P-value
N 67 63 54 110
Median age, years 47 32 57 51 <.01
Range 19-55 18-45 24-70 18-69
Age
#50 years 45 (67%) 63 (100%) 17 (32%) 51 (46%) <.01
>50 years 22 (33%) 0 37 (68%) 59 (54%)
Sex
Male 42 (63%) 35 (56%) 31 (57%) 64 (58%) .86
Female 25 (37%) 28 (44%) 23 (43%) 46 (42%)
KPS score at transplant
90-100 58 (87%) 51 (81%) 37 (69%) 88 (80%) .04
#80 4 (6%) 4 (6%) 11 (20%) 16 (14%)
Missing 5 (7%) 8 (13%) 6 (11%) 6 (6%)
Diagnosis
Acute myelogenous leukemia 20 (30%) 28 (44%) 19 (35%) 33 (30%) <.01
Acute lymphoblastic leukemia 9 (13%) 18 (29%) 2 (4%) 6 (5%)
Non-Hodgkin lymphoma 13 (19%) 8 (13%) 14 (26%) 23 (21%)
Hodgkin lymphoma 2 (3%) 0 2 (4%) 15 (14%)
Multiple myeloma 1 (2%) 1 (2%) 3 (6%) 3 (3%)
Myelodysplastic syndrome 9 (13%) 1 (2%) 5 (9%) 16 (14%)
Other 13 (19%) 7 (11%) 9 (17%) 14 (13%)
Disease risk
Standard 37 (55%) 24 (38%) 15 (28%) 38 (35%) .01
High 30 (45%) 39 (62%) 39 (72%) 72 (65%)
Previous transplant 0 0 15 (28%) 27 (24%) <.01
CMV serological status
Positive (donor or recipient) 30 (45%) 14 (22%) 24 (44%) 11 (10%) <.01
Negative 37 (55%) 49 (78%) 30 (56%) 99 (90%)
Graft source <.01
Peripheral blood 63 (94%) 51 (94%)
Bone marrow 4 (6%) 3 (6%)
UCB 63 (100%) 110 (100%)
Single UCB 3 5
Double UCB 60 105
HLA match*
6/6 64 (95%) 6 (10%) 49 (91%) 9 (8%) <.01
5/6 3 (5%) 17 (27%) 5 (9%) 31 (28%)
4/6 0 40 (64%) 0 70 (64%)
Median time to ANC engraftment, days 17 23 7 13 <.01
Range 9-26 7-38 0-30 0-60
Median time to platelet engraftment, days 25 56 15 47 <.01
Range 13-70 33-100 0-100 0-100
Graft failure 2 (3%) 12 (19%) 0 9 (8%) <.01
Second graft infusion 0 4 3
Medical encounters in first 100 days
Median hospital stay, days 39 48 23 38 <.01
Interquartile range 30-47 40-76 18-37 26-60
Median clinic visits, days 30 19 28 28 <.01
Interquartile range 17-38 9-32 13-38 9-38
Median total encounters, days 73 75 54 70 <.01
Interquartile range 53-83 59-93 42-67 57-91
Major complications
Dialysis 9 (13%) 10 (16%) 4 (7%) 10 (9%) .39
Mechanical ventilation 20 (30%) 25 (40%) 13 (24%) 28 (26%) .19
Hepatic veno-occlusive disease 5 (8%) 1 (2%) 0 3 (3%) .09
Median follow-up, months 31 25 38 25
Range 12-53 12-50 12-53 12-49
MRD indicates matched related donor; UCB, umbilical cord blood; MA, myeloablative; NMA, nonmyeloablative; KPS, Karnofsky performance status;
CMV, cytomegalovirus; HLA, human leukocyte antigen; ANC, absolute neutrophil count.
*Worst match for recipients of double UCB transplant.
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cost per day survived for patients who did not experi-
ence graft failure was $1105 (IQR, 679-2149) (P \
.001). UCB HCT was associated with higher total
costs even after patients with graft failure were ex-
cluded; median cost per day survived for MA andNMA MRD HCT recipients was $1005 and $612,
whereas that for UCB HCT recipients was $1703
and $1115, respectively (P\ .001).
Patients who received dialysis had a median total
cost per day survived of $4764 (IQR, 1194-6976) com-
pared to $1102 (IQR, 678-2209) among those who
Table 2. Univariate Analysis for Posttransplant Outcomes
100 Days
Posttransplant Outcomes MA MRD MA UCB NMA MRD NMA UCB P-Value
Overall survival 81 (71%-91%) 70 (59%-81%) 78 (67%-89%) 78 (70%-86%) .95
Treatment-related mortality 21 (11%-31%) 29 (17%-40%) 20 (10%-31%) 19 (12%-27%) .55
Grade iii-iv acute GVHD* 15 (6%-24%) 24 (13%-34%) 22 (11%-33%) 17 (10%-24%) .45
MRD indicates matched related donor; UCB, umbilical cord blood; MA, myeloablative; NMA, nonmyeloablative; GVHD, graft-versus-host disease.
*Cumulative incidence estimate.
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who received and did not receive mechanical ventila-
tion had total cost per day survived of $5099 (IQR,
1287-7570) and $977 (IQR, 614-1508), respectively
(P\ .001).DISCUSSION
In our contemporary cohort of adult HCT recipi-
ents, we observed the absolute costs of MA and NMA
UCB transplantation to be higher than MA and NMA
MRDtransplantation.However, the costs of transplan-
tation were primarily driven by severe posttransplant
complications (graft failure, dialysis, and mechanical
ventilation) and prolonged inpatient stay. UCB recipi-
ents have longer time to neutrophil and platelet
engraftment than MRD recipients. Because 1 of the
main endpoints for hospital discharge is engraftment,
it is not surprising thatUCB recipients had longer inpa-
tient stay with its associated costs (room and board,
pharmacy services, laboratory services, and blood com-
ponents). Also, graft failure was more common follow-
ingUCBHCT.Graft failure does increase the durationTable 3. Multivariate Analysis for Overall Survival at 100
Days
Variables*
Relative Risk
(95% Confidence Intervals) P-Value
Transplant type
MA MRD 1.0 .59
MA UCB 1.1 (0.7-1.6) .85
NMA MRD 0.8 (0.5-1.2) .21
NMA UCB 1.0 (0.6-1.5) .98
Graft failure
No 1.0 <.001
Yes 3.6 (2.2-5.9)
Dialysis
No 1.0 .001
Yes 2.1 (1.4-3.3)
Mechanical ventilation
No 1.0 <.001
Yes 4.4 (3.1-6.2)
MRD, matched-related donor; UCB, umbilical cord blood; MA, myeloa-
blative; NMA, nonmyeloablative.
*Other variables considered in the model included age at
transplantation, sex, KPS score at transplantation, disease risk, history
of previous transplant, CMV status, HLA match, graft source, acute
graft-versus-host disease, and occurrence of hepatic veno-occlusive dis-
ease.of hospitalization, and prolonged pancytopenia can
increase the risk of infectious complications and trans-
fusion requirements with a resultant increase in costs.
The cost of a second graft infusion, especially UCB,
also adds to this expense. Because the rates of severe
complications (excluding graft failure) were similar
among the 4 groups, the cost differences between
MRD and UCB are more likely a result of prolonged
hospitalization because of delayed engraftment and
graft failure rather than complications. Our study did
not address long-term costs of UCB transplantation.
There is emerging data that UCB HCT is associated
with a lower risk of chronic GVHD (cGVHD)
[14,17].Whether this would translate to lower or com-
parable costs versusMRD or matched unrelated donor
HCTover an extendedperiodof timeneeds tobe inves-
tigated.
The use of less intenseNMAconditioning does not
necessarily translate to lower costs. In our study, the cu-
mulative incidence of TRMwas similar between all al-
logeneic transplant types, regardless of donor source or
conditioning regimen intensity. Also, there was no dif-
ference in the rates of severe aGVHD, dialysis, me-
chanical ventilation, or hepatic VOD. Therefore, the
older age and/or poor health status of NMA HCT re-
cipients may offset the lesser toxicity of a reduced-in-
tensity conditioning (RIC) regimen. We observed
similar costs for MA and NMA MRD HCT. The oc-
currence of severe complications was amore importantTable 4. Costs of Allogeneic Hematopoietic Cell Trans-
plantation
Transplant Type* N
Cost per Day Survived, $
Median Interquartile Range
Myeloablative
MRD 67 1016 796-2232
UCB 63 2082 1306-6219
MUD† 7 1586 1282-3892
Nonmyeloablative
MRD 54 612 473-1023
UCB 110 1156 616-2472
MUD† 5 650 618-703
MRD indicates matched related donor; UCB, umbilical cord blood;
MUD, matched unrelated donor.
*Excluding costs of graft acquisition.
†Recipients of matched unrelated donor grafts were excluded from fur-
ther analyses.
Figure 1. Costs of transplantation by transplant type. Column height represents median costs per day survived. Categories of costs (as percent) for
each transplant type are also shown. Costs of graft acquisition were not included in this figure. (MA MRD, myeloablative matched related donor; MA
UCB, myeloablative umbilical cord blood; NMAMRD, nonmyeloablative matched related donor and NMAUCB, nonmyeloablative umbilical cord blood
transplantation).
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Other investigators have recently conducted cost anal-
yses comparing MA and NMA HCT. Saito et al. [8]
included 90 NMA and 185 MAHCT recipients trans-
planted between 2000 and 2003 in their retrospective
analysis. They showed that NMA HCT costs
approximately $53,030 less, and was associated with
16 fewer days of hospitalization than myeloablative
HCT within the first year after transplantation. InFigure 2. Categories of costs by tertiles of cost per day survived. The contrib
graft acquisition were excluded from this figure.another study, Cordonnier et al. [2] evaluated the
1-year costs of transplantation in 11 NMA and 12
MAHCT recipients with acute myelogenous leukemia
(AML) who were enrolled on a prospective trial be-
tween 1998 and 2003. There was a trend toward lower
costs of transplantation in the first 6 months for NMA
conditioning, but the costs from 6-12 months were
higher because of late complications and readmissions
and there was no difference in the costs of NMA andution of each category to total cost is represented as percent. Costs of
Table 5. Multivariate Analysis for Predictors of Costs of Al-
logeneic Transplantation
Variables*†
Relative Risk
(95% Confidence Intervals) P-Value
Transplant type
MA MRD 1.0
MA UCB 1.3 (1.1-1.5) .05
NMA MRD 1.0 (0.9-1.2) .82
NMA UCB 1.0 (0.8-1.2) .96
Graft failure
No 1.0
Yes 1.8 (1.7-1.9) <.001
Dialysis
No 1.0
Yes 1.3 (1.1-1.5) .05
Mechanical ventilation
No 1.0
Yes 1.3 (1.2-1.4) .004
Hospital stay, tertiles‡
<32 days 1.0
32-48 days 1.0 (0.8-1.2) .98
>48 days 2.1 (1.9-2.3) <.001
MRD indicates matched related donor; UCB, umbilical cord blood; MA,
myeloablative; NMA, nonmyeloablative.
*Other variables considered in the model included age at transplanta-
tion, KPS score at transplantation, disease risk, history of previous trans-
plant, CMV status, acute graft-versus-host disease, hepatic veno-
occlusive disease, and total medical encounters in days (by tertiles).
Graft source and HLA match correlated with transplant type and
were not included in the models as separate variables.
†Excluding costs of graft acquisition.
‡Total hospital stay in first 100 days posttransplantation.
Table 6. Key Patient and Transplant Characteristics De-
scribed by Cost Tertiles
Variable
Cost per day Survived (Tertiles)
<$830 $803-1805 >$1805
N 98 98 98
Median age in years (range) 51 (22-69) 44 (18-69) 44 (18-68)
KPS score at transplant #80 10 7 18
High disease risk 68 59 53
Previous transplant 12 12 18
CMV positive
(donor or recipient)
31 27 21
Conditioning regimen
and donor source
MA MRD 23 28 16
NMA MRD 35 12 7
MA UCB 2 25 36
NMA UCB 38 33 39
Median time to ANC
engraftment in days (range)
8 (0-38) 17 (0-32) 17 (5-60)
Graft failure 1 1 21
Major complications
Dialysis 4 8 21
Mechanical ventilation 10 16 60
Hepatic veno-occlusive
disease
1 2 6
Grade iii-iv acute GVHD 17 15 15
Median duration of hospital
stay (interquartile range)
23 (17-35) 40 (35-47) 61 (40-82)
KPS indicates Karnofsky performance status; CMV, cytomegalovirus;
MRD, matched related donor; UCB, umbilical cord blood; MA, myeloa-
blative; NMA, nonmyeloablative; ANC, absolute neutrophil count;
GVHD, graft-versus-host disease.
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patient population and transplant techniques (eg, con-
ditioning regimens) could explain the discrepant re-
sults from our and these 2 published studies. Some
observational studies have shown equivalent long-
term survival among patients receiving MA and NMA
HCT for selected diseases [16,18,19]. With similar
outcomes, the transplant modality with lesser costs
and lesser morbidity would be preferred. Hence,
more studies to better understand cost differences be-
tween MA and NMA conditioning regimens are
needed and any randomized trials comparing these 2
modalities should include economic and quality of
life endpoints.
The role of complications in increasing costs of
transplantationhasbeendescribedpreviously. Ina study
of 315MA allogeneic HCT recipients transplanted be-
tween 2000 and 2004, [7]. showed that themean cost of
transplantation in their cohort was $79,222, but severe
complications increased total costs by an average of
$20,228. [5]. have also shown that complications are
associated with higher costs. Their study included 181
patients who received a nMA allogeneicHCTbetween
1994 and 1997; the median initial inpatient cost was
$105,300 and occurrence of infection, hepatic VOD,
aGVHD, and death were predicted to add between
$15,300 and $28,100 each to the costs of transplanta-
tion.Prevention andearly recognition andmanagement
of complications, where possible, can decrease the costsof transplantation.Esperouet al. [3], in a studyof 85MA
allogeneic HCT recipients from 1998-2000, have also
shown that predictors of higher costs (adding an average
V20,000/patient) include transplant related complica-
tions, GVHD, and repeated infections.
Several limitations have to be considered in the in-
terpretation of our analysis. There exists considerable
practice variation in HCT among transplant centers,
and our results may not be generalizable. Also, we cap-
tured costswithin thefirst 100days following transplan-
tation and did not consider costs of long-term care or
management of cGVHD and its complications. Other
studies have shown that the costs of transplantation
are largely concentrated within the first 100 days [7].
We selected the early posttransplant period for investi-
gation because all medical care is conducted exclusively
at our center. Nevertheless, we could not account for
costs of outpatient prescription drugs and home-care
services. Transplant conditioning and GVHD prophy-
laxis and management regimens were dictated by spe-
cific protocols, and supportive care was based on
established guidelines, limiting the impact of practice
variation on costs.
We excluded costs of graft acquisition in cost anal-
yses because the characteristics of graft procurement,
storage, and processing are very different for MRD
andUCB.Given the resources needed for UCB collec-
tion and storage, UCB graft acquisition is much more
expensive than MRD. The contribution of graft
Figure 3. Predictors of costs of transplantation. Graft failure, dialysis use, use of mechanical ventilation, and prolonged hospital stay were associated
with increased costs. Costs of graft acquisition were not included in this figure. Column height represents proportion of patients within each group.
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cially because of its large dollar amount, and any strat-
egies to increase the cost effectiveness of UCB HCT
will also have to address these costs.
Because of the relatively small number of patients
who received a matched unrelated donor HCT, we
could not perform detailed analyses comparing costs
between matched unrelated donor and UCB trans-
plantation. Because UCB is primarily considered
among various alternative donor options for patients
without an MRD, future cost analyses comparing
matched unrelated donor and UCB HCT will be im-
portant. In our unadjusted descriptive analysis, trans-
plantation with matched unrelated donor was more
expensive than MRD but less expensive then UCB
for both MA and NMA conditioning regimens.
In conclusion, allogeneic HCT is a costly proce-
dure. In the first 100 days after transplantation, the
costs of MA and NMA MRD and nonmyeloablative
UCB transplantation are similar, whereas MA UCB
HCT is more expensive. Severe complications, graft
failure, and prolonged hospitalization are the major
contributors to total costs in the early posttransplant
period. Increased costs of UCBHCT are primarily be-
cause of longer hospitalization for delayed engraft-
ment and graft failure. Strategies to decrease the risk
of severe complications would reduce the overall costs
of transplantation in general. Methods to enhance en-
graftment and decrease the risk of graft failure in recip-
ients of UCB HCT would make this procedure more
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